335,855 Shares in Takeda Pharmaceutical Co. (NYSE:TAK) Bought by ABC Arbitrage SA

Key Points

• ABC Arbitrage SA has acquired 335,855 shares of Takeda Pharmaceutical Co. for approximately $4.99 million, making it the 28th largest holding in its investment portfolio.
• Takeda Pharmaceutical recently reported earnings per share (EPS) of $0.52, surpassing analysts' estimates of $0.47, although its revenue of $7.45 billion was below the consensus forecast of $7.96 billion.
• The company's stock has shown stability, with a current trading price of $14.27 and a market capitalization of $45.39 billion, reflecting a P/E ratio of 47.55.

ABC Arbitrage SA bought a new position in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 335,855 shares of the company's stock, valued at approximately $4,994,000. Takeda Pharmaceutical comprises approximately 0.9% of ABC Arbitrage SA's holdings, making the stock its 28th largest holding.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. FNY Investment Advisers LLC purchased a new position in Takeda Pharmaceutical in the 1st quarter worth approximately $37,000. Farther Finance Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical by 29.2% during the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock valued at $69,000 after purchasing an additional 1,045 shares in the last quarter. Fifth Third Bancorp boosted its position in shares of Takeda Pharmaceutical by 85.5% during the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock valued at $78,000 after buying an additional 2,411 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Takeda Pharmaceutical by 22.6% during the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after buying an additional 1,296 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in Takeda Pharmaceutical in the 4th quarter worth about $94,000. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK traded up $0.12 during trading on Thursday, reaching $14.39. 4,534,287 shares of the company traded hands, compared to its average volume of 5,594,319. The firm has a 50 day simple moving average of $14.83 and a 200-day simple moving average of $14.55. Takeda Pharmaceutical Co. has a 52-week low of $12.80 and a 52-week high of $15.53. The stock has a market capitalization of $45.77 billion, a PE ratio of 47.95 and a beta of 0.22. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The company had revenue of $7.45 billion for the quarter, compared to analysts' expectations of $7.96 billion. Equities research analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.